CompletedNCT00309699
Paliperidone, quetiapine, or placebo for mania in bipolarity
About this title
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
Read the official source — NCT00309699Researchers compared Paliperidone ER, placebo and Quetiapine to find out how the approaches affected manic symptoms in people with bipolarity.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Paliperidone ER, placebo and Quetiapine to find out how the approaches affected manic symptoms in people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Cerritos and 46 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 493
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Greece, Lithuania, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00309699
- Official title
Show the full official title
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes in Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedCerritos, United States · Garden Grove, United States · Oceanside, United States
46 more locations
- San Diego, United States
- Bradenton, United States
- Fort Lauderdale, United States
- Kissimmee, United States
- Maitland, United States
- South Miami, United States
- Tampa, United States
- Chicago, United States
- Indianapolis, United States
- Prairie Village, United States
- Lake Charles, United States
- Shreveport, United States
- Flowood, United States
- Clementon, United States
- Moore, United States
- Oklahoma City, United States
- Philadelphia, United States
- Memphis, United States
- Dallas, United States
- Athens, Greece
- Alytus, Lithuania
- Vilnius, Lithuania
- Kazan', Russia
- Lipetsk, Russia
- Moscow Region, Russia
- Moscow Russia, Russia
- Nizny Novgorod, Russia
- Saratov, Russia
- St-Petersburg Na, Russia
- Incheon, South Korea
- Seoul, South Korea
- Changhua, Taiwan
- Kaohsiung City, Taiwan
- Taichung, Taiwan
- Taipei, Taiwan
- Ankara, Türkiye
- Diyarbakır, Türkiye
- Istanbul, Türkiye
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Russia
- Türkiye
Questions about this study
What did researchers investigate?
Researchers compared Paliperidone ER, placebo and Quetiapine to find out how the approaches affected manic symptoms in people with bipolarity.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Quetiapine and Paliperidone ER.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
